Literature DB >> 2419684

Alpha 1-and alpha 2-adrenoceptor mediated vasoconstriction in the forearm of normotensive and hypertensive subjects.

K Jie, P van Brummelen, P Vermey, P B Timmermans, P A van Zwieten.   

Abstract

alpha 1- And alpha 2-adrenoceptor mediated vasoconstriction were studied in 13 patients with essential hypertension and 13 age-matched normotensive controls. This was done by comparing the changes in forearm blood flow induced by intra-arterial infusion of the selective alpha 1- and alpha 2-adrenoceptor agonists methoxamine and B-HT 933, the catecholamines adrenaline and noradrenaline, and the selective alpha 2-adrenoceptor antagonist yohimbine in both study groups. The catecholamines were infused in the presence of propranolol in order to prevent beta-adrenergic effects. Forearm blood flow was measured by plethysmography. All agonists produced a dose-dependent vasoconstriction which was more pronounced in the hypertensive patients, although the difference was significant only for the infusion of the catecholamines and for the combined effects of methoxamine and B-HT 933. No preference was found for either the alpha 1- or alpha 2-adrenoceptor mediated vasoconstriction in the greater response of the hypertensive patients. These results could well be explained by structural vascular changes, secondary to the elevated blood pressure. No evidence was found for increased alpha 2-adrenoceptor mediated basal vascular tone in patients with essential hypertension, since yohimbine tended to induce a greater vasodilatation in the normotensive subjects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419684     DOI: 10.1097/00005344-198601000-00028

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

Review 2.  Antihypertensive drugs interacting with alpha- and beta-adrenoceptors. A review of basic pharmacology.

Authors:  P A van Zwieten
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Drugs interacting with alpha adrenoceptors.

Authors:  P A van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

Review 4.  Antihypertensive treatment according to age, plasma renin and race.

Authors:  F R Bühler
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 5.  The role of serotonin in cardiovascular diseases and their treatment.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

6.  Further evidence for the existence of alpha 2-mediated adrenergic vasoconstriction in human vessels.

Authors:  S Taddei; A Salvetti; R Pedrinelli
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  The role of alpha- and beta-adrenoceptor blockade in antihypertensive treatment.

Authors:  P A van Zwieten
Journal:  Clin Investig       Date:  1992

8.  Cardiovascular actions of a new selective postjunctional alpha-adrenoceptor antagonist, SK&F 104856, in normotensive and hypertensive dogs.

Authors:  J P Hieble; A J Nichols; T A Fredrickson; P D DePalma; R R Ruffolo; D P Brooks
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

Review 9.  Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 10.  Different types of centrally acting antihypertensives and their targets in the central nervous system.

Authors:  P A van Zwieten; J P Chalmers
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.